



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

**Correction to
Lancet Infect Dis 2022;
published online April 21.
[https://doi.org/10.1016/
S1473-3099\(22\)00024-X](https://doi.org/10.1016/S1473-3099(22)00024-X)**

Folschweiller N, Vanden Abeele C, Chu L, et al. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial. *Lancet Infect Dis* 2022; published online April 21. [https://doi.org/10.1016/S1473-3099\(22\)00024-X](https://doi.org/10.1016/S1473-3099(22)00024-X)—In this Article, the final two sentences of the last paragraph in the Discussion section should have read “However, it was not possible to predict whether one chimeric construct has a higher potential over the others for the next stage of development of such universal vaccine.” This correction has been made to the online version as of May 2, 2022 and will be made to the printed version.

**Correction to
Lancet Infect Dis 2022;
22: 438–40**

Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19 vaccine schedules—to mix or not to mix? *Lancet Infect Dis* 2022; 22: 438–40—The appendix of this Comment has been corrected as of April 28, 2022.

**Correction to
Lancet Infect Dis 2022;
published online April 12.
[https://doi.org/10.1016/
S1473-3099\(21\)00744-1](https://doi.org/10.1016/S1473-3099(21)00744-1)**

Whittles LK, Didelot X, White PJ. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis. *Lancet Infect Dis* 2022; published online April 12. [https://doi.org/10.1016/S1473-3099\(21\)00744-1](https://doi.org/10.1016/S1473-3099(21)00744-1)—In the Summary of this Article, the first sentence of the Interpretation has been amended to “We recommend that vaccination of MSM against gonorrhoea according to risk in sexual health clinics in England with the 4CMenB vaccine be considered.” This correction has been made to the online version as of April 29, 2022, and will be made to the printed version.

**Correction to
Lancet Infect Dis 2022;
published online
April 4. [https://doi.
org/10.1016/S1473-
3099\(22\)00124-4](https://doi.org/10.1016/S1473-3099(22)00124-4)**

Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. *Lancet Infect Dis* 2022; published online April 4. [https://doi.org/10.1016/S1473-3099\(22\)00124-4](https://doi.org/10.1016/S1473-3099(22)00124-4)—In this Review, the spelling of author Rajeev Soman was incorrect. This correction has been made to the online version as of April 14, 2022, and will be made to the printed version.

**Correction to
Lancet Infect Dis 2022;
published online
March 31. [https://doi.
org/10.1016/S1473-
3099\(22\)00143-8](https://doi.org/10.1016/S1473-3099(22)00143-8)**

Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. *Lancet Infect Dis* 2022; published online March 31. [https://doi.org/10.1016/S1473-3099\(22\)00143-8](https://doi.org/10.1016/S1473-3099(22)00143-8)—In this Article, the first line of the Findings, in the Summary, should have read ‘Cohort 1 was comprised of 2 039 106 individuals, cohort 2 of 962 318 individuals, and cohort 3 of 567 810 individuals’. This correction has been made to the online version as of April 8, 2022, and will be made to the printed version.



Published Online
May 2, 2022
[https://doi.org/10.1016/
S1473-3099\(22\)00281-X](https://doi.org/10.1016/S1473-3099(22)00281-X)



Published Online
April 29, 2022
[https://doi.org/10.1016/
S1473-3099\(22\)00280-8](https://doi.org/10.1016/S1473-3099(22)00280-8)



Published Online
April 8, 2022
[https://doi.org/10.1016/
S1473-3099\(22\)00244-4](https://doi.org/10.1016/S1473-3099(22)00244-4)



Published Online
April 14, 2022
[http://dx.doi.org/10.1016/
S1473-3099\(22\)00268-7](http://dx.doi.org/10.1016/S1473-3099(22)00268-7)



Published Online
April 28, 2022
[http://dx.doi.org/10.1016/
S1473-3099\(22\)00278-X](http://dx.doi.org/10.1016/S1473-3099(22)00278-X)